Naphthalen-1-yloxymethyl-triazol-thiazol-cpd35a
BCHE specific: IC50 eleelACHE >600 microM eqBCHE 0.025 +/- 0.01 microM
General
Type : Naphthalen, Triazol, Thiazol, Sulfur Compound
Chemical_Nomenclature : 2-[(4-Allyl-5-((naphthalen-1-yloxy)methyl)-4H-1,2,4-triazol-3-yl)thio]-N-(thiazol-2-yl)acetamide
Canonical SMILES : C14=C(C=CC=C1OCC2=NN=C([N]2C=CC)SCC(NC3=NC=CS3)=O)C=CC=C4
InChI : InChI=1S\/C21H19N5O2S2\/c1-2-11-26-18(13-28-17-9-5-7-15-6-3-4-8-16(15)17)24-25-21(26)30-14-19(27)23-20-22-10-12-29-20\/h2-12H,13-14H2,1H3,(H,22,23,27)
InChIKey : ZNSSVVJVAQZGOK-UHFFFAOYSA-N
Other name(s) : Compound 35a || 2-[[5-(naphthalen-1-yloxymethyl)-4-allyl-1,2,4-triazol-3-yl]sulfanyl]-N-(1,3-thiazol-2-yl)propanamide
Target
Families : Naphthalen-1-yloxymethyl-triazol-thiazol-cpd35a ligand of proteins in family
BCHE
Protein :
human-BCHE
References (1)
| Title : Novel 1,2,4-triazole derivatives containing the naphthalene moiety as selective butyrylcholinesterase inhibitors: Design, synthesis, and biological evaluation - Kocak Aslan_2024_Arch.Pharm.(Weinheim)__e2400406 |
| Author(s) : Kocak Aslan E , Sezer A , Tuylu Kucukkilinc T , Palaska E |
| Ref : Arch Pharm (Weinheim) , :e2400406 , 2024 |
| Abstract : |
| PubMedSearch : Kocak Aslan_2024_Arch.Pharm.(Weinheim)__e2400406 |
| PubMedID: 39034293 |